Cachexia is a wasting disorder of adipose and skeletal muscle tissues that leads to profound weight loss and frailty. About half of all cancer patients suffer from cachexia, which impairs quality of life, limits cancer therapy and decreases survival. One key characteristic of cachexia is higher resting energy expenditure levels than in healthy individuals, which has been linked to greater thermogenesis by brown fat [1] [2] [3] [4] [5] [6] . How tumours induce brown fat activity is unknown. Here, using a Lewis lung carcinoma model of cancer cachexia, we show that tumour-derived parathyroid-hormone-related protein (PTHrP) has an important role in wasting, through driving the expression of genes involved in thermogenesis in adipose tissues. Neutralization of PTHrP in tumour-bearing mice blocked adipose tissue browning and the loss of muscle mass and strength. Our results demonstrate that PTHrP mediates energy wasting in fat tissues and contributes to the broader aspects of cancer cachexia. Thus, neutralization of PTHrP might hold promise for ameliorating cancer cachexia and improving patient survival.
Cachexia is a wasting disorder of adipose and skeletal muscle tissues that leads to profound weight loss and frailty. About half of all cancer patients suffer from cachexia, which impairs quality of life, limits cancer therapy and decreases survival. One key characteristic of cachexia is higher resting energy expenditure levels than in healthy individuals, which has been linked to greater thermogenesis by brown fat [1] [2] [3] [4] [5] [6] . How tumours induce brown fat activity is unknown. Here, using a Lewis lung carcinoma model of cancer cachexia, we show that tumour-derived parathyroid-hormone-related protein (PTHrP) has an important role in wasting, through driving the expression of genes involved in thermogenesis in adipose tissues. Neutralization of PTHrP in tumour-bearing mice blocked adipose tissue browning and the loss of muscle mass and strength. Our results demonstrate that PTHrP mediates energy wasting in fat tissues and contributes to the broader aspects of cancer cachexia. Thus, neutralization of PTHrP might hold promise for ameliorating cancer cachexia and improving patient survival.
Cachexia is a wasting disorder that accompanies many chronic diseases such as cancer and congestive heart failure. The hallmarks of cachexia are weight loss with atrophy of fat and skeletal muscle 7 . Importantly, cachexia is more than just anorexia [7] [8] [9] . Cachectic patients may ingest less food, but they are also in a state of negative energy balance that cannot be corrected by nutritional supplementation 8, 9 . As a negative risk factor for cancer survival, cachexia causes frailty in patients and often prevents them from undergoing further therapies. While cachexia can lessen with the shrinkage of tumours, there are currently few effective therapies for cancer cachexia 10, 11 . The molecular basis of cachexia is poorly understood. Elevated cytokine levels have been observed in cachectic patients, but anti-cytokine therapies are ineffective 10, 11 . The activation of brown fat has been described in rodent models of cachexia and in certain cachectic patients [1] [2] [3] [4] [5] [6] . Brown fat dissipates chemical energy in the form of heat and, hence, could be involved in the negative energy balance. How tumours induce thermogenesis in brown fat cells and how this might relate to the wasting of fat and skeletal muscle is unknown. In addition, white fat depots contain pockets of uncoupling protein 1 (UCP1)-expressing multilocular cells, called beige (or brite) cells, that can be stimulated on exposure to cold or other stimuli via a process termed browning. Recent studies have characterized beige cells at a molecular level 12 and have demonstrated a requirement for the transcriptional coregulator PRDM16 in the browning process 13 .
To understand the molecular basis of how tumours stimulate brown or beige cells, we used a murine model of lung cancer that is accompanied by cachexia: Lewis lung carcinoma (LLC).
LLC cells readily form tumours and lead to cachexia in syngeneic C57BL/6 mice. LLC-tumour-bearing mice demonstrated hypermetabolism: their rate of oxygen consumption was significantly higher than that of non-tumour-bearing mice (Fig. 1a) . However, this increase was not due to increased physical activity or reduced food intake (Extended Data Fig. 1a, b) . The lower carbon dioxide production relative to oxygen consumption (that is, the lowered respiratory exchange ratio) of LLC-tumour-bearing mice indicated that fat was the preferred source of fuel (Extended Data Fig. 1c, d ). Additionally, more heat production was observed in the cachectic mice.(Extended Data Fig. 1e ). All tumour-bearing mice lost weight over 3 weeks (Fig. 1b) , including wasting of adipose tissues and skeletal muscle (Fig. 1c) . Inguinal white adipose tissue (iWAT), a form of subcutaneous fat, wasted faster than epididymal fat (eWAT), a visceral white fat depot. In response to tumour growth, both white fat depots (eWAT and iWAT) and interscapular brown adipose tissue (iBAT) exhibited higher expression of genes involved in thermogenesis: Ucp1, Dio2 and Pgc1a (Fig. 1d-f ). An increase in the expression of certain other genes involved in energy metabolism, including glucose transporters and b-oxidation and lipolytic enzymes 14 , was also observed (Fig. 1d-f ). LLC tumours also induced the skeletal muscle expression of atrophy-associated genes (Fig. 1g) , including the genes encoding myostatin (Mstn), atrogin 1 (also known as Fbxo32) and MuRF1 (also known as Trim63).
To examine the contribution of adipose tissue browning to cachexia, we studied fat-specific Prdm16-deficient mice, which have a dramatically reduced thermogenic potential and are resistant to browning 13 . LLC-tumour-induced adipose tissue wasting was significantly inhibited in Prdm16-knockout mice, without a change in tumour size or the loss of muscle mass (Extended Data Fig. 2a, b) . The cachexia-associated induction of Ucp1 and Dio2 expression was impaired in the knockout mice, while the increase in expression of the other genes involved in energy metabolism was unaffected (Extended Data Fig. 2c-f) . These results indicate a crucial role for the beige fat thermogenesis pathway in adipose tissue wasting.
We examined whether LLC-tumour-derived factors may induce thermogenic gene expression in fat tissues. The treatment of primary white adipose cells with LLC-cell-conditioned medium stimulated the expression of Ucp1 and Dio2 (Fig. 2a) . We then filtered the LLC-cell-conditioned medium through a 3-kDa cut-off membrane and tested the response of primary adipocytes to each fraction (Fig. 2b) . All of the thermogenic activity was retained in the filter-concentrated fraction, leaving none in the flow-through. This finding suggests that the thermogenesis-inducing activity most probably originates from a macromolecule.
To identify thermogenic factors, we used a combination of cell cloning and gene expression profiling. We first established single-cell clones from the heterogeneous LLC cells. Thirty subclones were generated and used to produce conditioned media, the activity of which was then tested on primary adipocytes. We observed a range of Ucp1-inducing activity by conditioned media from these subclones (Fig. 2c) , and we chose eight clones that demonstrated either more or less thermogenic activity than the parent cells (Extended Data Fig. 3a) . We analysed the global gene expression profiles of the 8 subclones using microarrays and generated a list of secreted proteins for which the corresponding messenger RNA levels were higher in the more thermogenic subclones (Fig. 2d) . We tested the effects of these secreted proteins on primary adipocytes and found that several members of the epidermal growth factor (EGF) family (Extended Data Fig. 3b ), including betacellulin (BTC), heparin-binding EGFlike growth factor (HBEGF) and epiregulin (EREG), as well as PTHrP (encoded by Pthlh), induced Ucp1 expression (Fig. 2e) .
To determine the contribution of BTC, EREG and HBEGF to the Ucp1-inducing activity found in LLC-cell-conditioned medium, we used an inhibitor of EGF receptor (EGFR) signalling. Since the three EGF family proteins signal through the receptors EGFR and ERBB4, we tested the effects of AST-1306, a specific protein kinase inhibitor that targets both receptors, on primary adipocytes. AST-1306 completely blocked Ucp1 mRNA induction when fat cells were treated in combination with BTC, EREG or HBEGF (Extended Data Fig. 3c ). By contrast, the browning activity present in LLC-cell-conditioned medium was largely unaffected by AST-1306 treatment, suggesting that these EGF family proteins do not have a major quantitative role in this process (Fig. 3a) .
PTHrP is processed into at least three peptide products. We treated primary white and brown adipocytes with these peptides and PTH(1-34) (a PTH-derived peptide containing amino acid residues 1 to 34), which has sequence and structural similarity to PTHrP(1-34). Both PTH(1-34) and PTHrP(1-34), which signal through the same receptor (the PTH and PTHrP receptor (PTHR)), stimulated thermogenic gene expression ( Fig. 3b and Extended Data Fig. 3d ). For simplicity, hereafter, the 1-34 peptides will be referred to as PTHrP and PTH. Time-course and dose-response analysis of PTHrP treatment revealed that this peptide potently induces Ucp1 and Dio2 mRNA (by up to 200-and 20-fold, respectively), comparable to noradrenaline, the classic thermogenic catecholamine produced by the sympathetic nervous system (Fig. 3c and Extended Data Fig. 4 ). We next investigated how PTHrP affects UCP1 protein levels and uncoupled respiration. Primary white and brown adipocytes were treated with noradrenaline, PTHrP or PTH. Remarkably, all three factors comparably increased UCP1 protein levels and significantly raised oxygen consumption, including basal, uncoupled and maximal respiration (Extended Data Fig. 5a-c) . These results show that the PTH and PTHrP pathway can be a robust regulator of cellular respiration.
PTHR is a G-protein-coupled receptor that activates the cyclic-AMPdependent protein kinase (PKA) pathway 15 . Noradrenaline also signals through b-adrenergic receptors that are G-protein-coupled receptors and induce PKA signalling, thereby promoting thermogenic gene expression. The treatment of primary white and brown adipocytes with noradrenaline, PTHrP or PTH stimulated the phosphorylation of the PKA substrates CREB and HSL. A selective PKA inhibitor, H89, blocked PKA signalling, which also completely inhibited transcriptional regulation by all three factors (noradrenaline, PTHrP and PTH) (Extended Data Fig. 5d-g ). These results strongly suggest that both PTHrP and PTH require the PKA pathway to mediate their effects on Ucp1 and Dio2 transcription and therefore have a signalling mechanism in common with the b-adrenergic pathway.
Next, a neutralizing antibody specific for PTHrP was used to investigate whether PTHrP is involved in LLC-cell-induced thermogenic gene expression. This antibody was capable of completely inhibiting ) for 24 h (n 5 3). The mRNA levels corresponding to the indicated genes were determined by qRT-PCR. Ap2 (also known as Fabp4) and Pparg are controls for adipocyte differentiation. The values are mean 6 s.e.m. Statistical analysis was conducted using the two-tailed t-test. *, P , 0.05; **, P , 0.005; ***, P , 0.0005, compared with the control group. Relative mRNA level were inoculated with LLC cells and monitored for up to 21 days (n 5 6 for each group). Four days after inoculation, a cohort of mice (n 5 6 for the nontumour-bearing (NTB) group and n 5 9 for the LLC group) was placed into metabolic cages to measure oxygen consumption (VO 2 ) (a). Carcass weight (calculated by subtracting tumour weight from the total weight) (b) and the weight of fat and muscle tissues (c) were measured. The mRNA levels in iWAT (d), eWAT (e), iBAT (f) and the gastrocnemius muscle (Gastroc) (g) were determined by quantitative reverse transcription PCR (qRT-PCR). The values are mean 6 s.e.m. Statistical analysis was conducted using the two-tailed t-test. *, P , 0.05; **, P , 0.005; ***, P , 0.0005 compared with the NTB group. d, day.
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PTHrP activity when added to adipocytes (Fig. 3d) . Importantly, when adipocytes were treated with LLC-cell-conditioned medium in combination with the anti-PTHrP antibody, Ucp1 and Dio2 induction was almost completely blocked (Fig. 3e ). These data indicate that PTHrP is a major component of the LLC-cell-secreted products that cause browning of cultured adipocytes.
PTHR (which is encoded by Pth1r) is known to be highly expressed in the kidneys and bone 15 . Notably, rather high Pth1r mRNA expression was also observed in adipose and muscle tissues (Extended Data Fig. 6a ). We next investigated PTHrP-dependent transcriptional regulation in vivo. PTHrP potently promoted the expression of thermogenic genes and certain other genes of energy metabolism (Extended Data Fig. 6b -e), a pattern that is notably similar to the browning of adipose tissues by LLC tumours.
The role of PTHrP in LLC-tumour-induced fat browning and wasting was then investigated. Up to 500 pg ml 21 PTHrP was detected in the plasma of tumour-bearing mice (Fig. 4a) . We next injected mice with the neutralizing antibody specific for PTHrP or control IgG. Amazingly, anti-PTHrP-treated mice did not experience significant weight loss, while the IgG-treated group displayed evident cachexia (Fig. 4b) . The anti-PTHrP treatment blocked both adipose tissue and skeletal muscle wasting, without changing the average tumour mass (Fig. 4c, d ). Histological examination of the adipose tissues showed that anti-PTHrP treatment prevented the shrinkage of fat droplets (Fig. 4e) . This neutralization of PTHrP also blocked thermogenic gene expression in eWAT, iBAT (Fig. 4f, g ) and iWAT (Extended Data Fig. 7 ), indicating that thermogenesis has a causal role in fat wasting. Treatment with anti-PTHrP antibody also lowered the oxygen consumption of the cachectic mice, increased their physical activity and reduced their heat production ( Fig. 4h and Extended Data Fig. 8 ). We used a Clark electrode to test ex vivo oxygen consumption of fat and skeletal muscle tissues. Notwithstanding the limited power of this technique to measure and represent actual tissue respiration, we demonstrated modest increases in the fat tissue respiration of the cachectic mice. These increases were suppressed by the antiPTHrP treatment (Extended Data Fig. 9 ).While additional, off-target, effects of the anti-PTHrP antibody cannot be ruled out, these data reveal a major role for PTHrP in LLC-tumour-induced adipose tissue thermogenesis and hypermetabolism.
Neutralization of PTHrP also reduced the LLC-tumour-induced muscle wasting (Fig. 4d) , the atrophy of muscle fibres (Extended Data  Fig. 10a ) and the atrophy-associated gene expression (Fig. 5a) . We further The mRNA levels in eWAT (f) and iBAT (g) were measured by qRT-PCR. h, Mice were treated similarly to b-g except that they were placed into metabolic cages on day 4 to measure oxygen consumption (n 5 6 for the NTB group and n 5 5 for the other groups). The values are mean 6 s.e.m. Statistical analysis was conducted using the two-tailed t-test. *, ** and *** denote differences between the NTB group and the IgG group. #, ## and ### denote differences between the anti-PTHrP group and the IgG group. *, P , 0.05; **, P , 0.005; ***, P , 0.0005; #, P , 0.05; ##, P , 0.005; ###, P , 0.0005. activity. a-c, Primary adipocytes (n 5 3 for each group) were treated with 1 mM AST-1306 and LLC-cell-conditioned medium for 24 h (a), with 100 ng ml 21 of the indicated peptides for 2 h (b), or with 100 ng ml 21 PTHrP for 2-24 h or 100 mM noradrenaline (NE) for 4 h (c). d, e, Primary adipocytes (n 5 3 for each group) were treated with 10 mg ml 21 IgG or anti-PTHrP antibody along with either 10 ng ml 21 PTHrP for 4 h (d) or LLC-cellconditioned medium for 24 h (e). The mRNA levels were measured by qRT-PCR. The values are mean 6 s.e.m. Statistical analysis was conducted using the two-tailed t-test. *, ** and *** denote differences from the control (IgG) group. #, ## and ### denote differences between the PTHrP groups or between the LLC groups. *, P , 0.05; **, P , 0.005; ***, P , 0.0005; #, P , 0.05; ##, P , 0.005; ###, P , 0.0005.
RESEARCH LETTER
investigated this effect by treating mice with anti-PTHrP antibody until the time point at which severe cachexia was observed in the controls. The anti-PTHrP treatment preserved muscle mass to a significant extent (Fig. 5b, c) . This preservation was also reflected in muscle function, as shown by improved grip strength and in situ muscle contraction (Fig. 5d, e) . While it was possible that PTHrP-associated hypercalcaemia may have confounded the effects here, we did not observe hypercalcaemia in the LLC model, and neutralization of PTHrP did not affect the circulating calcium levels (Extended Data Fig. 10b, c) .
PTHrP injection into healthy mice failed to affect the expression of muscle-atrophy-associated genes (Extended Data Fig. 10d, e) . Furthermore, PTHrP treatment of primary myotubes did not change the expression of the muscle-atrophy-associated genes or myotube diameter (Extended Data Fig. 10f, g ), suggesting that PTHrP does not directly induce skeletal muscle atrophy. We investigated this further by injecting PTHrP into tumour-bearing mice. Remarkably, PTHrP administration exacerbated cachexia-associated weight loss without changing tumour mass (Extended Data Fig. 10h-j) . PTHrP treatment led to more severe skeletal muscle wasting and poorer muscle function and significantly promoted the expression of muscle-atrophy-associated genes in the cachectic mice ( Fig. 5f-h ). These findings indicate that PTHrP is required for the loss of muscle mass and function in the LLC model. However, PTHrP probably does not act alone and is likely to collaborate with other tumourderived factors.
Lastly, we investigated PTHrP expression in a cohort of patients diagnosed with metastatic non-small-cell lung cancer or colorectal cancer, whose body composition and metabolic rate were studied in the context of a clinical investigation of the aetiology of cancer cachexia [16] [17] [18] . Seventeen out of 47 patients displayed detectable levels of serum PTHrP (mean 6 s.d., 205 6 155 pg ml
21
) with no medical history of hypercalcaemia. These patients had a significantly lower lean body mass (LBM) and a significantly higher resting energy expenditure (REE) per kg LBM than 30 patients lacking detectable levels of PTHrP (Fig. 5i, j) . The reduced amount of lean tissue in the PTHrP-positive patients was not associated with a difference in dietary intake (PTHrP-positive, 2,364 6 750 kcal day PTHrP is secreted by many tumours and is often involved in the hypercalcaemia that accompanies certain cancers 19 . PTHrP has previously been linked to the cachexia associated with hypercalcaemia of malignancy [20] [21] [22] . However, its direct roles in the muscle wasting process and the browning of adipose tissues have not been reported. Taken together, our data show that PTHrP is the major LLC-tumour-derived factor stimulating adipose tissue thermogenic gene expression and hypermetabolism. Neutralization of PTHrP blocks both the browning and the wasting of fat depots and much of the muscle wasting and weakness in this model of cachexia.
These data suggest a model whereby PTHrP functions alone to drive the thermogenic/browning program in adipose tissues but is likely to collaborate with other tumour-derived molecules to bring about the profound muscle wasting and weakness observed in the LLC model (Fig. 5k) . The identity of the collaborating factors is unknown. The browning driven by PTHrP seems not to be obligatorily linked to the muscle wasting process.
Our preliminary evaluation of 47 patients with cancer identified a PTHrP-positive subset, which showed features of reduced LBM and increased REE. Further prospective studies on cachexia-prone patients should study these parameters with serial tissue biopsies to determine whether there is a specific association between PTHrP, adipose tissue browning and metabolic rate in clinical cancer cachexia. If PTHrP is involved in cachexia in certain patients, it should be possible to identify those with elevated PTHrP levels. A humanized antibody specific for PTHrP might have anti-cachectic effects like those shown here. It will also be interesting to determine whether elevated PTHrP or PTH levels have any roles in the cachexia that is associated with certain other diseases, such as congestive heart failure and chronic kidney diseases. The gastrocnemius muscle weight (f) and grip strength (g) were measured. The mRNA levels in the gastrocnemius muscle were determined by qRT-PCR (h). i, j, The LBM and REE/LBM of the PTHrP-positive and PTHrP-negative patients were compared. k, A model for PTHrP action in cancer cachexia. a, c-j, The values are mean 6 s.e.m. Statistical analysis was conducted using the two-tailed t-test. *, ** and *** denote differences from the NTB group. #, ## and ## denote differences between the IgG group and the anti-PTHrP group or between the LLC-Vehicle group and the LLC-PTHrP group. *, P , 0.05; **, P , 0.005; ***, P , 0.0005; #, P , 0.05; ##, P , 0.005; ###, P , 0.0005.
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METHODS
Materials. All recombinant proteins used in this study were purchased from R&D Systems, except STC1 (BioVendor) and tumour-necrosis factor-a (TNF-a) (Sigma). Synthetic PTHrP and PTH peptides, the PTHrP(1-34) enzyme-linked immunosorbent assay (ELISA) (S-1227) and the anti-PTHrP(1-34) (T-4512) antibody were purchased from Bachem. Normal rabbit IgG (Santa Cruz Biotechnology, sc-2027; and R&D Systems, AB-105-C) was used as a control for the anti-PTHrP antibody. All other antibodies were purchased from Cell Signaling Technology, including antibodies specific for total HSL (#4107), phospho-HSL (#4126), total CREB (#9197), phospho-CREB (#9198), phospho-PKA substrate (#9624), phospho-Akt (#4060) and phospho-ERK1/2 (#9101), except anti-UCP1 (Abcam, ab10983) and anti-tubulin (Santa Cruz Biotechnology, sc-9935) antibody. Noradrenaline and AST-1306 were purchased from Sigma and Tocris, respectively. Animals. All animal experiments were approved by the Institutional Animal Care and Use Committee of the Beth Israel Deaconess Medical Center. Mice (Mus musculus) were maintained in 12 h light:dark cycles (6 a.m.-6 p.m.) at 22 uC and fed a standard irradiated rodent chow diet. Prdm16-floxed mice ( 6 adiponectinCre) were maintained on a pure C57BL/6 background. All other animals were lean C57BL/6 mice obtained from Charles River Laboratories. Six-to-ten-week-old male mice were used in all animal experiments. Sample size, determined empirically via performing preliminary experiments, was chosen to be at least four to ensure that adequate statistical power was achieved. Mice were divided into treatment groups randomly while satisfying the criteria that the average body weight in each group would be about the same. Treatment groups were clearly marked to avoid mistakes (no blinding). LLC cells (5 3 10 6 per mouse) were injected subcutaneously over the flank. Non-tumour-bearing control mice received vehicle (PBS) only. Mice received intraperitoneal injections of IgG and anti-PTHrP antibody and subcutaneous injections of the PTHrP peptide. Non-tumour-bearing mice received IgG or vehicle (PBS). All mice were killed in the late light cycle (3 p.m.-6 p.m.). Mice were housed individually in all tumour inoculation experiments and in groups in other experiments. Plasma was collected into EDTA-containing tubes for the PTHrP(1-34) ELISA assay. Peptide-free rat serum (Bachem) was used as the standard diluent to correct for the background reading of mouse plasma samples. Heparin-containing tubes were used to collect plasma for calcium measurements, which were performed with a VITROS analyser. Whole-body energy metabolism was evaluated using a Comprehensive Laboratory Animal Monitoring System (CLAMS, Columbus Instruments). Carbon dioxide and oxygen data were collected every 32 min for each mouse and were normalized to total body weight. Data on activity, heat generation and food intake were measured at more frequent intervals. For haematoxylin and eosin staining, adipose tissues were fixed in 4% formaldehyde, embedded in paraffin and cut into 6-mm sections on slides. Primary white adipocyte culture. Inguinal stroma-vascular fractions were obtained from 30-35-day-old male mice using the following procedure. Inguinal fat tissue was dissected, washed with PBS, minced and digested for 45 min at 37 uC in PBS containing 10 mM CaCl 2 , 2.4 U ml 21 dispase II (Roche) and 1.5 U ml 21 collagenase D (Roche). Digested tissue was filtered through a 100-mm cell strainer and centrifuged at 600g for 5 min to pellet the stroma-vascular cells. The pellets were then resuspended in adipocyte culture medium (DMEM/F12 (1:1, Invitrogen) plus GlutaMAX, penicillin and streptomycin, and 10% FBS), filtered through a 40-mm cell strainer, centrifuged as above, resuspended in adipocyte culture medium and plated. The stroma-vascular cells were grown to confluence for adipocyte differentiation, which was induced by an adipogenic cocktail containing 1 mM dexamethasone, 5 mg ml 21 insulin, 0.5 mM isobutylmethylxanthine (DMI) and 1 mM rosiglitazone in adipocyte culture medium. Two days after induction, cells were maintained in adipocyte culture medium containing 5 mg ml 21 insulin and 1 mM rosiglitazone. Starting on day 6, cells were maintained in adipocyte culture medium only and treated with various molecules for 2-24 h and harvested on day 8. Primary brown adipocyte culture. Interscapular brown fat pads were dissected from newborn mice (postnatal days 2-4), minced and digested for 45 min at 37 uC in an isolation buffer containing 123 mM NaCl, 5 mM KCl, 1.3 mM CaCl 2 , 5.0 mM glucose, 100 mM HEPES, 4% BSA and 1.5 mg ml 21 collagenase B (Roche). Digested tissue was filtered through a 100-mm cell strainer and centrifuged at 600g for 10 min. Pelleted stroma-vascular cells were resuspended in adipocyte culture medium (described above) and plated. Stroma-vascular cells were grown to confluence for adipocyte differentiation, which was induced by an adipogenic cocktail containing 5 mM dexamethasone, 0.02 mM insulin, 0.5 mM isobutylmethylxanthine, 1 nM T3, 125 mM indomethacin and 1 mM rosiglitazone in adipocyte culture medium. Two days after induction, cells were maintained in adipocyte culture medium containing 0.02 mM insulin, 1 nM T3 and 1 mM rosiglitazone. Starting on day 4, cells were maintained in adipocyte culture medium only, treated with various molecules for 2-24 h and harvested on day 8. LLC cell culture and conditioned medium preparation. LLC cells were maintained in DMEM (Invitrogen) with 10% FBS, and penicillin and streptomycin. For conditioned medium collection, cells were plated at a 1:3 confluence. The following day, the medium was changed to the FreeStyle expression medium (Invitrogen) and was then collected 24 h later. For fractionation, the LLC-cell-conditioned medium was filtered using a 3-kDa cut-off filter (Millipore). Adipocytes were treated with conditioned medium for 24 h starting 7 days after the differentiation protocol. When adipocytes were treated with conditioned medium, the treatment medium was composed of 50% fresh adipocyte culture medium and 50% LLC-cell-conditioned medium. When conditioned medium was filtered and concentrated, adipocytes were exposed to 90% adipocyte culture medium and 10% concentrated LLC-cellconditioned medium. For the analysis of global gene expression, LLC clones were cultured in FreeStyle expression medium for 24 h. RNA was extracted using TRIzol (Invitrogen) and purified with QIAGEN RNeasy minicolumns. GeneChip Mouse Genome 430 2.0 arrays (Affymetrix) were used to generate expression profile data, which were analysed using dChip software. Gene expression analysis (qRT-PCR). RNA was extracted from cultured cells or frozen tissue samples using TRIzol, purified with QIAGEN RNeasy minicolumns and reverse transcribed using a High-Capacity cDNA Reverse Transcription kit (Applied Biosystems). The resultant cDNA was analysed by qRT-PCR. Briefly, 25 ng cDNA and 150 nmol of each primer were mixed with SYBR GreenER qPCR SuperMix (Invitrogen). Reactions were performed in the 384-well format using an ABI PRISM 7900HT instrument (Applied Biosystems). Relative mRNA levels were calculated using the comparative CT method and normalized to cyclophilin mRNA. The following primers were used: cyclophilin F: 59-GGAGATGGCACAGGAGGAA-39, R: 59-GCCCGTAGTGCTTCAGCTT-39; Ucp1 Western blotting. Cells were homogenized in a lysis buffer containing 50 mM Tris (pH 7.4), 500 mM NaCl, 1% NP40, 20% glycerol, 5 mM EDTA and 1 mM phenylmethylsulphonyl fluoride (PMSF) supplemented with protease and phosphatase inhibitor cocktails (Roche). The homogenates were centrifuged at 13,000 r.p.m. for 10 min, and the supernatants were used as whole-cell lysates. Protein concentration was determined by Bio-Rad protein assay, and 50 mg protein lysate was separated in each SDS-PAGE lane. The separated proteins were transferred to a polyvinylidene difluoride (PVDF) membrane, which was blotted with antibodies in TBS containing 0.05% Tween (TBS-T) and 5% BSA. For secondary antibody incubation, TBS-T containing 5% milk was used. Enhanced chemiluminescence (ECL) western blotting substrates (Pierce) were used for visualization of the results. Respiration assays. The cellular oxygen consumption rate (OCR) of primary adipocytes was determined using an XF24 Extracellular Flux Analyzer (Seahorse Bioscience). Primary adipocytes were cultured and differentiated in XF24 microplates and treated with noradrenaline, PTHrP or PTH at 7 days post differentiation. Twenty-four hours later, adipocyte culture medium was changed to DMEM lacking NaHCO 3 but containing 10 mM glucose, 1 mM pyruvate and the treatment chemicals. The uncoupled and maximal OCRs were determined using 1 mM oligomycin and 1 mM FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone), respectively. Complex-I-dependent respiration was inhibited with 3 mM rotenone. Ex vivo tissue respiration was measured using a Clark electrode (Strathkelvin Instruments) as described previously 13 . Freshly isolated tissues were briefly minced and transferred to the electrode chamber containing a respiration buffer consisting of 13 DPBS (Dulbecco's phosphate-buffered saline), 2% BSA, 25 mM glucose and 1 mM pyruvate. Oxygen consumption values were normalized to tissue weight. Grip strength. Forelimb grip strength was assessed on the same day as killing 23 . Each mouse was allowed to grab a bar attached to a force transducer as the mouse was pulled by the tail horizontally away from the bar (DFX II Series force gauge; Chatillon). The
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results from five repetitions with a 30-s pause between each were averaged to determine the grip strength of each mouse. In situ muscle force measurements. In situ force was measured as described previously 24 . Briefly, mice were anaesthetized with a subcutaneous injection of a cocktail of ketamine, xylazine and acepromazine (1.4 ml per kg body weight). The distal tendon of the gastrocnemius muscle was cut just before the insertion at the ankle. The tendon was tied with a 4.0 nylon suture and attached to an isometric transducer. The sciatic nerve was exposed with an incision in the hamstring region. The sciatic nerve was then cut as close to the hip bone as possible and dissected from the surrounding fascia. The exposed sciatic nerve was then laid over two electrodes with a small piece of parafilm placed under the suspended nerve to prevent contact with other tissues. The nerve was kept moist by periodic treatment with mineral oil. The nerve was stimulated using a supramaximal square-wave pulse of 0.1 ms duration. Measurements were made at the length at which the maximal tension was obtained during the twitch (L o ). Data were recorded for maximal (P o ; stimulation frequency of 75-150 Hz) isometric force. Primary myoblast culture. Primary myoblasts were isolated from male mice ,14 days old and cultured in Ham's F-10 nutrient mixture (Irvine Scientific) containing 20% FBS (Gemini Bio-Products) supplemented with 2.5 ng ml 21 basic fibroblast growth factor (bFGF) (Promega), penicillin G (200 U ml
21
) and streptomycin (200 mg ml 21 ). Myoblasts were then transferred to differentiation DMEM with 5% horse serum until mature myotube formation (,48-72 h) and then treated with PTHrP or TNFa. The diameters of individual myotubes were measured using ImageJ software. Human study. This was a further analysis of a study designed to investigate the metabolic, nutritional and functional profile of a cohort of patients recently diagnosed with advanced non-small-cell lung cancer (stages IIIB or IV) or colorectal cancer (stage IV) (n 5 47) [16] [17] [18] . The inclusion criteria and measures have been described elsewhere [16] [17] [18] . The patients were recruited from the Cross Cancer Institute, a cancer treatment centre serving Edmonton and Northern Alberta, Canada. The study was approved by the Alberta Cancer Board Research Ethics Board, and all participants provided written informed consent. Patients with advanced lung or colorectal cancer were included in the study because of their high susceptibility to weight loss and cachexia associated with cancer. All participants were under the direct care of a medical oncologist and received the standard chemotherapy for their disease and stage. None of the patients was receiving medications with the intent of managing cachexia (for example, corticosteroids, progestational agents or cannabinoids).
Participants were asked to fast for 12 h and to refrain from strenuous exercise and alcohol for 24 h before assessments, which included body composition measurement, REE measurement and a blood sample assessment. The PTHrP(1-34) ELISA assay was used to determine the serum PTHrP level. Serum samples collected from normal subjects were used to set the baseline for measuring the blood PTHrP level. Serum PTHrP measurements were performed in a blinded fashion. The REE measurement was made by indirect calorimetry (VMax 29N, SensorMedics) as described previously 16 . Participants rested for 30 min, after which a canopy was placed over their head and shoulders for 30 min to analyse oxygen consumption and carbon dioxide production. Breath samples were measured until a steady state was reached for 15 min. The Weir equation was used to calculate the REE. On the same morning as the REE assessment, all participants also underwent a dual-energy X-ray absorptiometry (DXA) scan (Lunar Prodigy High Speed Digital Fan Beam X-Ray-Based Densitometer with enCORE 9.20 software, GE Healthcare) to measure whole-body fat mass and fat-free mass 17 . Blood samples drawn for C-reactive protein assessment were taken and analysed in the hospital clinical laboratory. Three-day diet records (detailing intake for three consecutive days, including one weekend day) were used to assess total energy intake and meal patterns. Records were reviewed for accuracy and completeness. Three-day dietary records have been shown to provide accurate mean estimates of group dietary intake in patients with advanced cancer 18 . Statistical analysis. For every experiment, sample size was determined empirically (preliminary experiments were performed) to ensure that the desired statistical power could be achieved. The values are expressed as mean 6 s.e.m. The error bars (s.e.m.) shown for all results were derived from biological replicates, not technical replicates. Significant differences between two groups were evaluated using a twotailed, unpaired t-test, which was found to be appropriate for the statistics, as the sample groups displayed a normal distribution and comparable variance. RESEARCH LETTER
